Fundz

Pierrepont Therapeutics reported raising $2.11 Million in an initial SEC Form D filing, from an offering of $5.86 Million

PRIVATEApr 15, 2024$2.1M of $5.9M raised

Amount Raised

$2.11 Million

$2.11 Million sold, per SEC Form D (first sale Apr 2, 2024)

Round Type

Seed

BrooklynBiotechnologyHealthcare

Who to call at Pierrepont Therapeutics, and when

A new round usually means Pierrepont Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Pierrepont Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Pierrepont Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Pierrepont Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Pierrepont Therapeutics

Location

DOWNSTATE TECHNOLOGY CENTER, SUITE 327A

Brooklyn, New York, United States

About

Pierrepont Therapeutics, Inc. is dedicated to developing targeted treatments for primary mitochondrial and other rare genetic diseases. Pierrepont's lead product candidate, PTI-501 (formerly ENTR-501) is a proprietary intracellular enzyme replacement therapy for the treatment of MNGIE that is exclusively licensed from Entrada Therapeutics, Inc. (Nasdaq: TRDA). The founders of Pierrepont have unique expertise and success in mitochondrial disease drug development, and have strong relationships with KOLS, families, and patient advocacy groups in the mitochondrial disease community.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Pierrepont Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Pierrepont Therapeutics's next move

See what Strategic adds

Pierrepont Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.